Advertisement

Topics

Latest AstraZeneca NewsRSS

00:09 EDT 17th October 2017 | BioPortfolio

STAT Plus: Pharmalittle: AstraZeneca acknowledges fabrication; how industry undermined opioid enforcement

AstraZeneca acknowledged an early study supporting a cancer drug that was the centerpiece of a $4 billion acquisition was falsified.

FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1

Positive opinion is based on Phase III trial data demonstrating a 4.9 month progression-free survival improvement with combination over fulvestrant alone2 AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for Fasl...

Adherium Wins 2017 OBN Award for Best Implementation of Digital Healthcare

San Mateo, CA - October 10, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, has won ‘Best Implementation of Digital Healthcare’ at the prestigious OBN Awards 2017. The awards celebrate innovation and achievement across the UK life sciences industry and the winners were selected by an esteemed panel of judges. The Best Im...

Why AstraZeneca PLC CEO Took a Job His Friends Called a Suicide Mission

When Pascal Soriot was offered the chance to run AstraZeneca Plc in 2012, the British drugmaker lagged in developing immuno-therapies, a new frontier for cancer research; it was poised to lose about $17 billion of sales through 2018 due to expiring patents; and its slate of new medicines appeared lackluster. The situation was so bleak that one colleague told him it would be suicidal to sign up. So...

Avara buys French site: AZ talks what, why and where to next

Following the announced sale of AstraZenecaâs solid dose facility to Avara, the former outlines the Reims, France-based sites capabilities, and tells us why it is letting it go.

CLVS Seeks New Use For Rubraca, TNDM Effects Reverse Stock Split, MDXG On Watch

Today's Daily Dose brings you news about AstraZeneca's lung cancer drug TAGRISSO getting Breakthrough Therapy Designation; Clovis' seeking approval for expanded indication of its ovarian cancer drug; MiMedx Group's share repurchase program and Tandem Diabetes' reverse stock split.

AstraZeneca’s Cancer Treatment Gets Breakthrough Therapy Designation

The FDA has granted AstraZeneca’s lung cancer treatment Breakthrough Therapy Designation, indicating that it offers big improvement compared with current options. A sixth AstraZeneca cancer treatment since 2014 has received a Breakthrough Therapy Designation. The candidate, Tagrisso, targets non-small cell lung cancer by ... This awesome article AstraZeneca’s Cancer Treatment Gets B...

Avara buys AZ solid dose facility in France

Avara Pharmaceutical Services will buy AstraZenecaâs secondary solid dosage form manufacturing, packaging and distribution facility in Reims, France.

Avara Acquires Secondary Solid Dosage Form Manufacturing, Packaging And Distribution Facility From AstraZeneca PLC In France

  Life Sciences Jobs   ...

FDA Calls AstraZeneca PLC's Targrisso a Breakthrough

  Life Sciences Jobs   ...

#jobs #lifescience MedImmune: Process Technician

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MedImmune: Process Technician . Negotiable: MedImmune: Title: Process Technician – Manufacturing Location: Liverpool, UK Salary: Competitive MedImmune is the global biologics research and development arm of AstraZeneca. We … Continue reading → Cet article #jo...

AstraZeneca PLC May Move Some Manufacturing, R&D Out of the UK Due to Brexit

  Life Sciences Jobs   ...

Federal Court of Appeal Applies Supreme Court's Utility Test to SPRYCEL Patent

In its first decision to consider the Supreme Court of Canada's landmark decision in AstraZeneca Canada Inc v Apotex Inc , 2017 SCC 36 [ Esomeprazole ] on the utility requirement, the Federal Court of Appeal has overturned a finding of inutility made under the promise doctrine, with practical guidance for the requirement of a scintilla of utility: Bristol-Myers Squibb v Apotex , 2017 FCA 190 ....

Prostate Cancer [2016]: Bulletin 3 [Report Updated: 01072017] Prices from USD $1045

Gain new key opinion leader KOL insights on the latest events happening in prostate cancer.Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating JJ's Zytiga abiraterone plus prednisone, in combination with androgen deprivation therapy ADT in patients with hormonenave prostate cancer HNPC; KOL views on the results published in the Cancer ...

NewLink inks deal with AstraZeneca to test Imfinzi combo

IDO inhibitors like NewLink's indoximod are seen as a potentially fruitful pairing for PD-L1 inhibitors.   

Inhalation Sciences Gets Large Order From AstraZeneca

STOCKHOLM, Sept. 27, 2017 /PRNewswire/ -- Inhalation Sciences (ISAB) has received an order for a complete PreciseInhale system, including all its test modules, from AstraZeneca. ISAB, which recently carried out an oversubscribed share issue ahead of its listing on AktieTorget in Stockholm, develops and sells advanced lab equipment for inhalation R&D that measures how particles in inhal...

Inhalation Sciences Gets Large Order From AstraZeneca PLC

  Life Sciences Jobs   ...

AstraZeneca PLC's COPD Drug Bevespi Aerosphere Scores a Phase III Win

  Life Sciences Jobs   ...

Why AstraZeneca PLC's 'Big Pipeline' Makes it a Possible Take-Out Candidate

  Life Sciences Jobs   ...

AstraZeneca Canada Release: First-In-Class BRCA-Positive Ovarian Cancer Medicine Lynparza (Olaparib) Receives Positive Pan-Canadian Oncology Drug Review (pCODR) Recommendation For Provincial Reimbursement

  Life Sciences Jobs   ...

GSK, AstraZeneca and Labcyte Form Alliance to Develop Acoustic Mass Spectrometry – a Novel Sample Handling Technology for MS-based Drug Discovery

The post GSK, AstraZeneca and Labcyte Form Alliance to Develop Acoustic Mass Spectrometry – a Novel Sample Handling Technology for MS-based Drug Discovery appeared first on SynBioBeta.

Respiratory Inhalers Market to Witness Comprehensive Growth of 6.1% by 2023

Market Research Future adds new report of "Respiratory Inhalers Market Research Report- Global Forecast To 2023" it contains Company information, geographical data and Table of Content Competitive Analysis: Some of the key players in this market are: - Adherium limited - AstraZeneca - Boehringer Ingelheim GmbH - Chiesi Farmaceutici S.p.A. - GSK plc. - Propeller Health - Teva Pharmaceutical Industr...

GSK, AstraZeneca and Labcyte Form Alliance to Develop Acoustic Mass Spectrometry - a Novel Sample Handling Technology for MS-based Drug Discovery

Labcyte Inc. today announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications. Acoustic liquid dispensing, pioneered by Labcyte, uses the gentle energy of sound waves to move ...

GlaxoSmithKline, AstraZeneca PLC And Labcyte Inc. Form Alliance To Develop Acoustic Mass Spectrometry - A Novel Sample Handling Technology For MS-Based Drug Discovery

  Life Sciences Jobs   ...

Recipharm to make clinical trial cancer candidate for Kancera

Recipharm will make clinical trial capsules to support oncology candidate KAND567, a former AstraZeneca Fractalkine receptor inhibitor being developed by Kancera.

Quick Search
Advertisement
 

review and buy AstraZeneca market research data and corporate reports here